Novo - QuikReader

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says

The FDA's decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

CNBC - Feb. 21

Novo’s Weight Loss Drugs Removed from FDA Shortage List

The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list.

Inc. - Feb. 22

Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss ...

The Hill - 13h

Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

MarketWatch - Feb. 25

Novo Nordisk goes direct to consumer with Wegovy. What it means for obesity rival Eli Lilly

Shares of Eli Lilly rose Wednesday despite its rival's announcement.

CNBC - 14h

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

ABC News - 14h

Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.